Moldable Calcium Phosphate Bone Graft Substitute

    Building on Biomatlante’s core MBCP™ Technology, In’Oss™ is an innovative and moldable bone graft, composed of Hydroxyapatite (HA), Beta Tricalcium Phosphate (ß-TCP) and a hydrogel.
    Developed to facilitate handling during bone grafting procedures, In’Oss™ can fit into different grafting sites.
    In’Oss™, is the optimal balance between MBCP™ micro granules and an absorbable hydrogel, acting as a carrier for rapid vascularization and mineralization.
    In’Oss™ keeps the original graft shape and bone volume. It is gradually absorbed to be replaced by vital architectured bone.

    MBCP™ Technology’s Key Features


    Provides a matrix for new bone growth

    Molecular mixture of HA and TCP

    HA alone resorbs too slowly while TCP resorbs too fast. Bi-phasic HA and TCP allow for a resorption rate similar to that of human bone.

    70% porosity, similar to cancellous bone

    Interconnected network of macropores and micropores that enables the colonization of bone cells and biological fluid uniformly within the matrix.


    For ionic exchange: TCP dissolution and bone crystal precipitation. Newly bioactive interface with bone cells.


    Macropores are a network of interconnected spaces that promote the biological infiltration and cellular colonization by osteoblasts and osteoclasts.


    Micropores are the intercrystalline spaces where dissolution and recrystallisation occurs.

    >30 years of clinical experience

    Host bone formation is systematically demonstrated.


    100% synthetic – 5 years shelf life.

    1. The safety and efficacy of an injectable bone substitute in dental sockets demonstrated in a human clinical trial. Weiss P., Layrolle P., Clergeau LP., Enckel B., Pilet P., Amouriq Y., Daculsi G., Giumelli B., Biomaterials. 2007 Aug;28(22):3295-305.
    2. Maxillary Sinus Bone Grafting with an Injectable Bone Substitute: a Sheep Study, A.Saffarzadeh, O. Gauthier, and al., Key Engineering Materials Vols. 254-256 (2004) p. 193-196
    3. Tricalcium phosphate/hydroxyapatite biphasic calcium phosphate (BCP) bioceramics , in Bioceramics and theirs clinical applications, Daculsi G., LeGeros R., T. Kokubo editor, Woodhead publishing, 2008, pp 395-4242
    4. A New Injectable Bone Substitute Concept (MBCP Gel ™): First Clinical Results in Human Maxillo-Facial Surgery, Pierre Weiss, Léon Philippe Clergeau, Bénédicte Enckel, Yves Amouriq, Bernard Giumelli, Alain Jean and Guy Daculsi, Key Engineering Materials Vols. 284-286 (2005) pp. 1053-1056
    5. Five Years Clinical Follow up Bone Regeneration with CaP Bioceramics Clemencia Rodríguez, Alain Jean, and Guy Daculsi, Key Engineering Materials Vols. 361-363(2008) pp. 1339-1342
    6. Assessment of Cancellous Bone Architecture after Implantation of an Injectable Bone Substitute, Catherine A. Davy, O. Gauthier, and al., Key Engineering Materials Vols. 254-256 (2004) pp. 55-5842

    In’oss™ is intended only for bony voids or gaps that are not intrinsic to the stability of the bony structure.
    • Maximum contact between the product and the recipient bone must be established.
    • Do not overfill defects.
    • In’oss™ does not harden after implantation until bone rehabilitation. The device should be secured to prevent motion and migration, use in areas where the graft can be adequately contained.
    • Do not leave defect open. (e.g. mucosa well sutured and/or use of appropriate membrane).
    • Do not compromise blood supply to the defect area.
    • In’oss™ has to be in direct contact of at least 2 or 3 surfaces. Maximum contact between In’oss™ and recipient bone must be achieved.
    • In’oss™ does not harden after implantation until healing. In’oss™ is a void filler used in cavity with respected corticals or associated with an osteosynthesis device. To avoid any possibility of leakage out of the cavity of implantation, bone flap or resorbable membrane can be associated.
    • Adequate post-operative immobilization is to be used with In’oss™ to prevent movement that may lead to soft tissue ingrowth.
    • Until healing is complete In’oss™ may not withstand weight bearing. Post surgery discharge is necessary.
    • Implantation is not recommended in revision surgery site containing non resorbable biomaterials residues. Preoperative and operating procedures, including knowledge of surgical techniques and proper selection and placement of the implant are important considerations in the successful utilization of this device.
    • The product has not been tested on pregnant women. The risk of health has not been established.

    • ISO 13485
    • Read the instructions for use
    • MBCP™ is supplied sterile and CE-marked as a Class III Medical Device according to Directive EEC/93/42

    CE 0123

    Certain products may not be approved for sale in all countries.



    • Sinus Lift Augmentation
    • Ridge augmentation
    • Alveolar regeneration


    • Intra-osseous pockets
    • Furcations


    MBCP™ Putty is available in:

    0.5ml – 2×0.5ml

    Related Products

    Back to Top

    Be contacted by our sales team to distribute our products!

    We will never give away, trade or sell your email address. You can unsubscribe at any time.

    Be contacted by our sales team to distribute our products!

    We will never give away, trade or sell your email address. You can unsubscribe at any time.